Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Download Data

Theseus Pharmaceuticals Inc Days in Inventory for the quarter ending September 30, 2023

Theseus Pharmaceuticals Inc Days in Inventory is NA for the quarter ending September 30, 2023. The days in inventory ratio measures the average number of days it takes for a company to sell its inventory. It is calculated by dividing 365 by the ratio of cost of revenue to the average of inventory and other current assets. This ratio indicates the efficiency of inventory management and the company's ability to convert inventory into sales within a specific period. A lower number of days in inventory is generally preferable.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends